We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Apr 14, we issued an updated research report on Rexnord Corporation .
In the past three months, this Zacks Rank #3 (Hold) stock has returned 12.5% compared with the industry’s growth of 3.3%.
Present Scenario
Rexnord has been benefiting from operational execution, supply-chain optimization and surge in e-commerce business. Also, the company’s business diversity has been allowing it to mitigate the adversities in one end market with strength across others. Notably, it is working diligently to expand its prospects in the hygiene market.
Also, the company believes in strengthening and expanding its businesses through acquisitions. Notably, it acquired Just Manufacturing Co. and Canada-based Hadrian Inc. in calendar 2020. Both acquired assets have been integrated with Rexnord’s Water Management segment. Notably, acquired assets boosted the company’s sales by 1% in the quarter ended Dec 31, 2020.
Moreover, Rexnord is committed to rewarding shareholders through share repurchases and dividend payouts. For instance, in the nine months ended December 2020, the company paid out dividends worth $28.8 million to shareholders besides repurchasing shares worth $59.3 million.
However, weakness in the Process & Motion Control segment, primarily in the aerospace business poses a major concern for Rexnord. For the first quarter of 2021, it anticipates sales for Process & Motion Control to decline in the low-double-digit range on a year-over-year basis.
Further, the company has been experiencing rising costs and expenses over time. Notably, in the quarter ended Dec 31, 2020, its cost of sales and selling, general and administrative expenses recorded an increase of 2.9% and 14.5%, respectively. Higher costs and expenses might prove detrimental to Rexnord’s performance in the quarters ahead.
II-VI delivered a positive earnings surprise of 83.68%, on average, in the trailing four quarters.
Regal Beloit delivered a positive earnings surprise of 31.56%, on average, in the trailing four quarters.
Middleby delivered a positive earnings surprise of 22.98%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Rexnord (RXN) Displays Strong Prospects, Headwinds Persist
On Apr 14, we issued an updated research report on Rexnord Corporation .
In the past three months, this Zacks Rank #3 (Hold) stock has returned 12.5% compared with the industry’s growth of 3.3%.
Present Scenario
Rexnord has been benefiting from operational execution, supply-chain optimization and surge in e-commerce business. Also, the company’s business diversity has been allowing it to mitigate the adversities in one end market with strength across others. Notably, it is working diligently to expand its prospects in the hygiene market.
Also, the company believes in strengthening and expanding its businesses through acquisitions. Notably, it acquired Just Manufacturing Co. and Canada-based Hadrian Inc. in calendar 2020. Both acquired assets have been integrated with Rexnord’s Water Management segment. Notably, acquired assets boosted the company’s sales by 1% in the quarter ended Dec 31, 2020.
Moreover, Rexnord is committed to rewarding shareholders through share repurchases and dividend payouts. For instance, in the nine months ended December 2020, the company paid out dividends worth $28.8 million to shareholders besides repurchasing shares worth $59.3 million.
However, weakness in the Process & Motion Control segment, primarily in the aerospace business poses a major concern for Rexnord. For the first quarter of 2021, it anticipates sales for Process & Motion Control to decline in the low-double-digit range on a year-over-year basis.
Further, the company has been experiencing rising costs and expenses over time. Notably, in the quarter ended Dec 31, 2020, its cost of sales and selling, general and administrative expenses recorded an increase of 2.9% and 14.5%, respectively. Higher costs and expenses might prove detrimental to Rexnord’s performance in the quarters ahead.
Key Picks
Some better-ranked stocks are II-VI Incorporated , Regal Beloit Corporation (RBC - Free Report) and The Middleby Corporation (MIDD - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
II-VI delivered a positive earnings surprise of 83.68%, on average, in the trailing four quarters.
Regal Beloit delivered a positive earnings surprise of 31.56%, on average, in the trailing four quarters.
Middleby delivered a positive earnings surprise of 22.98%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>